Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib, Lenalidomide, and Rituximab in First-line Mantle Cell Lymphoma
NCT05076097Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2021
- Primary completion
- Oct 2022
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in mantle cell lymphoma (MCL), sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
orelabrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05076097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05076097.